Related Experiment Video

Updated: May 21, 2026

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment
10:33

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment

Published on: April 25, 2025

Engineering folate-drug conjugates to target cancer: from chemistry to clinic

Iontcho R Vlahov1, Christopher P Leamon

  • 1Endocyte Inc., 3000 Kent Avenue, West Lafayette, IN 47906, USA.

Bioconjugate Chemistry
|June 7, 2012
PubMed

Insights

Folate receptor (FR) targeted therapies show promise for cancer management. This review details the conjugation chemistries used to create folate-based small-molecule drug conjugates (SMDCs) for cancer imaging and treatment.

Area of Science:

  • Oncology
  • Bioconjugation Chemistry
  • Molecular Targeting

Background:

  • The folate receptor (FR) is a membrane protein that binds extracellular folates with high affinity.
  • FR facilitates the intracellular delivery of folates via endocytosis.
  • This physiological system can be leveraged for targeted delivery of therapeutics to cancer cells.

Purpose of the Study:

  • To review the conjugation chemistries for constructing folate-based small-molecule drug conjugates (SMDCs).
  • To highlight the application of FR-targeted strategies in cancer management.
  • To focus on modular design, hydrophilic spacers, and self-immolative linkers in SMDC development.

Main Methods:

  • Review of existing literature on folate receptor targeting.
  • Analysis of conjugation chemistries for small-molecule drug conjugates.
  • Focus on specific linker and spacer strategies in SMDC design.

Main Results:

  • Preclinical and clinical evidence supports FR-positive cancer identification and treatment using folate conjugates.
  • Folate-targeted chemotherapies demonstrate efficacy in FR-positive cancers.
  • Various conjugation methods enable the development of active folate-based drug conjugates.

Conclusions:

  • Folate receptor targeting is a viable strategy for cancer diagnosis and therapy.
  • Understanding conjugation chemistry is crucial for developing effective folate-based SMDCs.
  • Modular design, hydrophilic spacers, and self-immolative linkers are key components in SMDC construction.

More Related Videos

Synthetic Methodology for Asymmetric Ferrocene Derived Bio-conjugate Systems via Solid Phase Resin-based Methodology07:07

Synthetic Methodology for Asymmetric Ferrocene Derived Bio-conjugate Systems via Solid Phase Resin-based Methodology

Published on: March 12, 2015

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer02:18

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...